Agenda

Session Introduction

Seth A. Wander, MD, PhD

‍

Focused Learning Session

Seth A. Wander, MD, PhD

‍

Novel Antiestrogen Agents and Dynamic ctDNA Monitoring for HR+/HER2- MBC

Katherine DiNardo, MD

‍

Targeting the PI3K Pathway: Rational Drug Design and New Strategies

‍

After Endocrine Resistance: Antibody Drug Conjugates for Metastatic HR+ Breast Cancer

‍

Audience Q&A and Panel Discussion

Seth A. Wander, MD, PhD; Katherine DiNardo, MD